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Abstract: The mainstream treatment for recurrent pancreatic cancer is potent chemotherapy or
chemoradiotherapy. However, recent clinical investigations have suggested a potential oncologic
role of local resection of recurrent pancreatic cancer. This systemic review with a pooled analysis
aimed to assess the potential role of local repeated pancreatectomy with respect to the survival
outcomes for patients with recurrent pancreatic ductal adenocarcinoma (PDAC) in the remnant
pancreas. The PubMed database was searched, and 15 articles reporting on repeated pancreatectomy
for local recurrence of PDAC in the remnant pancreas were identified. The pooled individual
data were examined for the clinical outcomes of repeated pancreatectomy for recurrent PDAC.
The survival analysis was performed using the Kaplan–Meier method. In the pooled analysis,
the mean time interval from initial pancreatectomy to repeated pancreatectomy was 41.3 months
(standard deviation (SD), 29.09 months). Completion total pancreatectomy was most commonly
performed as repeated pancreatectomy (46 patients, 92.0%), and partial pancreatic resection was
performed for only 4 (10.3%) patients. Twenty (40.9%) patients received postoperative chemotherapy
following repeated pancreatectomy. The median overall survival was 60 months (95% confidential
interval (CI): 45.99–74.01) after repeated pancreatectomy for isolated local recurrence in the remnant
pancreas. Overall survival was markedly longer considering the timing of the initial pancreatectomy
for pancreatic cancer (median, 107 months (95% CI: 80.37–133.62). The time interval between the initial
and subsequent repeated pancreatectomy for pancreatic cancer was not associated with long-term
oncologic outcomes (p = 0.254). Repeated pancreatectomy cannot completely replace adjuvant
chemotherapy but should be considered for patients with isolated local recurrent PDAC in the
remnant pancreas.
Keywords: completion total pancreatectomy; pancreatic ductal adenocarcinoma; pooled analysis;
recurrent pancreatic cancer; repeated pancreatectomy; survival
1. Introduction
Despite low resection rates at the initial diagnostic stage, margin-negative resection is the only
strategy to ensure long-term survival when treating patients with pancreatic cancer. However,
recurrence is high in patients with resected pancreatic cancer. Up to 80% of patients who undergo
curative pancreatectomy will experience systemic or local recurrence within 2 years [1]. According to
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the available literature, isolated local recurrence without systemic metastasis is reported in up to 30%
of patients [2,3].
International consensus concerning the role of surgical management for patients with isolated
local recurrence of pancreatic ductal adenocarcinoma (PDAC) in the remnant pancreas has not been
achieved. Importantly, an adequate number of cases of treatment for isolated local recurrence of PDAC
in the remnant pancreas have not been documented; therefore, the treatment required for recurrent
PDAC has not been discussed in detail. The mainstream treatment for isolated local recurrence of
PDAC in the remnant pancreas was potent chemotherapy or chemoradiotherapy. However, recent
clinical investigations have suggested a potential oncologic role of local resection of recurrent pancreatic
cancer [4–6]. This study aimed to evaluate the potential role of repeated pancreatectomy for isolated
local recurrence of PDAC in the remnant pancreas using a pooled analysis, and to scrutinize the
oncologic significance of the reported studies on repeated pancreatectomy so far.
2. Materials and Methods
2.1. Search Strategy and Data Sources
An extensive literature review was conducted according to the 2009 Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guidelines [7]. The PubMed (MEDLINE) database
was searched for articles published between January 2000 and April 2020 using the following terms:
remnant pancreatic cancer, pancreatic cancer, pancreatectomy, pancreatic resection, local neoplasm
recurrence, completion pancreatectomy, remnant pancreas, pancreatic ductal adenocarcinoma, recurrent
pancreatic cancer, and second pancreatectomy. The variables of interest included sex, age, surgical
procedures, disease-free interval between the initial pancreatectomy and appearance of remnant PDAC,
R status (Resection margin status), adjuvant chemotherapy, 30-day mortality, and overall survival (OS).
Isolated local recurrence of PDAC was defined as first recurrence limited to the remnant pancreas.
2.2. Inclusion and Exclusion Criteria
The inclusion criteria were (1) repeated pancreatectomy for isolated locally recurrent pancreatic
cancer limited to the remaining pancreas after pancreatic resection, (2) evaluation of at least one of
the clinicopathological or survival characteristics, (3) published original articles or case reports that
contained original data, and (4) cases with pathologically confirmed ductal adenocarcinoma and with
data available on both individualized long-term survival and time interval. All studies that did not
meet the inclusion criteria were excluded. In addition, the following exclusion criteria were applied:
(1) absence of data for individual patients, (2) other types of pancreatic cancer except pancreatic
ductal adenocarcinoma, and (3) written in languages other than English. Two independent reviewers
(MSC and CMK) reviewed all the retrieved studies that met the inclusion and exclusion criteria by
manually screening the articles. Discrepancies between the two reviewers were resolved by discussion
and achieving a team consensus.
2.3. Statistical Analysis
All statistical analyses were performed using SPSS Statistical software (version 25.0; SPSS Inc.,
Chicago, IL, USA). The continuous variables were expressed as means ± standard deviations or ranges,
and the categorical variables were expressed as frequencies or percentages. The Student’s t-test was
used to compare the continuous variables, and the chi-square tests and Fisher’s exact tests were
used to compare the categorical data. The Kaplan–Meier method was used for the analysis of the
OS. To identify the potential factors predicting the OS, univariate and multivariate analyses of the
clinicopathological variables were performed using Cox-proportional hazard regression models with
backward elimination. A p-value < 0.05 was considered statistically significant.
J. Clin. Med. 2020, 9, 3945 3 of 11
3. Results
3.1. General Characteristics of the Patients
A total of 727 potential studies were identified. Overall, 692 studies were excluded on reviewing the
title and abstract. Thirty-five studies were selected for full-text review [3,4,6,8–38]. Of these, 15 studies
met the inclusion criteria and were included in our pooled analysis [8,11–15,17,21,23–25,29–31,39]
(Figure 1). The 15 studies are summarized in Table 1.
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Figure 1. Flow chart for study selection.
The overall incidence of isolated local recurrence in the remnant pancreas was reported in 8
of 15 articles and showed a distribution of 0.3–5.3%. Among 50 patients, 18 male and 32 female
patients with a mean age of 65.0 (range 57.15–72.85) years were identified. Pancreaticoduodenectomy
was performed for 32 (64.0%) patients, distal pancreatectomy for 17 (34.0 ) patients, and partial
pancreatic resection for 1 (2.0%) patient as the initial pancreatecto y for pancreatic cancer. The ean
ti e interval fro initial pancreatecto y to repeated pancreatecto y was 41.3 (range 12.21–70.39)
onths. Completion total pancreatectomy was most com only performed as repeated pancreatectomy
(46 patients, 92.0%), and partial pancreatic resection was performed for only 4 (10.3%) patients. Twenty
(40.9%; missing data, 17 patients, 34.0%) patients received postoperative chemotherapy following
repeated pancreatectomy (Table 2).
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Table 1. Characteristics of the selected studies.
Author, Year Study Design Incidence †, % n
1st Operation Time Interval (Months, Mean) 2nd Operation OS (Months, Median)
PD/DP/PP CTP/PP
Eriguchi, 2000 [8] Case report NA 1 0/1/0 88.0 1/0 8.0
Takamatsu, 2005 [11] Case report NA 1 1/0/0 47.0 1/0 10.0
Dalla Valle, 2006 [12] Case report NA 1 1/0/0 15.0 1/0 24.0
Miura, 2007 [13] Case series,single center 2.3 1 1/0/0 20.0 1/0 44.0
Tajima, 2008 [14] Case report NA 1 1/0/0 37.0 1/0 38.0
Koizumi, 2010 [15] Case report NA 2 1/1/0 59.5 2/0 9.0
Lavu, 2011 [17] Case series,single center 1.3 3 2/1/0 68.0 3/0 8.0
Shimoike, 2013 [21] Case report NA 2 1/1/0 18.0 2/0 24.0
Boone, 2013 [23] Case series,single center NA 6 6/0/0 29.9 4/2 31.0
Hashimoto, 2014 [24] Case series,single center 2.6 6 3/3 29.7 6/0 15.5
Miyazaki, 2014 [25] Case series,single center 5.3 9 6/3/0 32.7 8/1 28.0
Shima, 2015 [39] Case series,single center 3.2 6 4/2/0 28.8 5/1 27.5
Ishida, 2016 [29] Case series,single center 0.8 1 0/1/0 53.0 1/0 21.0
Sahakyan, 2016 [30] Case report 0.3 1 1/0/0 36.0 1/0 4.0
Suzuki, 2016 [31] Case series,single center 1.1 9 4/4/1 64.7 9/0 15.0
PD, pancreaticoduodenectomy; DP, distal pancreatectomy with or without splenectomy; CTP, completion total pancreatectomy; PP, partial pancreatectomy. † Incidence, isolated local
recurrence in the remnant pancreas/total resected pancreatic cancer.
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Table 2. Characteristics of the patients undergoing repeated pancreatectomy for recurrent pancreatic
ductal adenocarcinoma included in the pooled analysis.
n = 50
Age 65.0 ± 7.85
Sex, male 18 (40.9)





Combined resection 11 (22.0)
R status, 1st OP
R0 43 (91.5)
R1 or R2 4 (8.5)
Adjuvant CTx., 1st OP 25 (58.1)
Time interval 41.3 ± 29.09
Type of 2nd OP
CTP 46 (92.0)
PP 4 (10.3)
R status, 2nd OP
R0 32 (84.2)
R1 or R2 6 (15.8)
30-day mortality 0 (0.0)
90-day mortality 1 (2.0)
Adjuvant CTx., 2nd OP 20 (40.9)
OP, operation; PD, pancreaticoduodenectomy; DP, distal pancreatectomy with or without splenectomy; TP, total
pancreatectomy; PP, partial pancreatectomy; CTx, chemotherapy; CTP, completion total pancreatectomy.
3.2. Long-Term Oncologic Outcomes
The median OS was 60 (95% confidential interval (CI): 45.9–74.0) months after repeated
pancreatectomy for isolated local recurrence in the remnant pancreas (Figure 2A). The median OS was
markedly longer if the follow-up duration was calculated from the time of the initial pancreatectomy
(107 months, 95% CI: 80.3–133.0, Figure 2B). The time interval between the initial and repeated
pancreatectomy was not associated with the long-term oncologic outcome of repeated pancreatectomy
(p = 0.254; Figure 2C). In univariate analysis, the time interval between the initial and repeated
pancreatectomy, R1 resection, and adjuvant chemotherapy were not associated with the OS after
repeated pancreatectomy (Table 3).J. Clin. Med. 2020, 9, x FOR PEER REVIEW 6 of 11 
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Table 3. Univariate analysis of the predictors of overall survival after repeated pancreatectomy.
Variables HR 95% CI p-Value
Time interval
≤24 months 0.280
24 < months ≤ 60 0.460 0.152–1.390 0.169
>60 months 1.096 0.308–3.907 0.887
R1 resection, repeated pancreatectomy 2.785 0.287–27.007 0.377
Adjuvant CTx after repeated pancreatectomy 3.704 0.788–17.418 0.097
CTx, chemotherapy; CI, confidence interval.
3.3. Short-Term Operative Outcomes
Of those 50 patients, none experienced 30-day mortality, and only one patient died within
90 days after repeated pancreatectomy. Postoperative complications mentioned explicitly in the
literature were delayed gastric emptying (n = 2), intra-abdominal abscess (n = 4), sepsis (n = 1),
focal hepatic infarction (n = 1), and subcutaneous abscess (n = 1). Among all 50 cases, 11 did not
mention postoperative complications.
4. Discussion
In this study, we aimed to evaluate the potential role of local repeated pancreatectomy for recurrent
PDAC in the remnant pancreas, and we found that repeated pancreatectomy improved the survival
outcomes for patients with isolated local recurrent PDAC in the remnant pancreas. Pancreatic cancer is
considered one of the dismal malignant diseases in the gastrointestinal system. Only margin-negative
resection is essential for long-term survival; however, the resection rate at diagnostic stage is low,
and recurrence is commonly noted within 2 years, even after radical pancreatectomy [40]. Finally, disease
progression leading to cancer-related mortality during chemotherapy is inevitable in patients with
recurrence. However, this clinical scenario may not always hold true owing to the recent changes in
clinical oncology, such as the development of advanced surgical techniques, perioperative management
strategies, and improved potent chemotherapeutic agents.
Unlike systemic recurrence, isolated local recurrence of pancreatic cancer is considered a topic
of interest for pancreatic surgeons because recurrence can be controlled by local treatment, such as
repeated pancreatectomy, in selected patients. Especially, considering the potential role of neoadjuvant
chemotherapy in treating pancreatic cancer, chemotherapy for local recurrence in the remnant pancreas
followed by repeated pancreatectomy may potentially be an option for treating isolated local recurrent
pancreatic cancer [41]. Neoadjuvant chemotherapy is used for treating isolated recurrence of pancreatic
cancer in the remnant pancreas with the aim of treating possible microscopic systemic metastasis that
cannot be detected, and assessing tumor biology for selecting the appropriate patients.
With respect to the long-term oncologic outcomes of repeated pancreatectomy for isolated local
recurrence of pancreatic cancer, Yamada, et al. reported 114 patients with remnant pancreatic cancer
after initial pancreatectomy [6]. Ninety patients underwent repeated pancreatectomy; the median
survival was 26 months, which was superior to that noted for patients who did not undergo resection
(hazard ratio (HR): 0.56, p = 0.012). Hashimoto et al. reviewed 12 published studies reporting
on recurrent pancreatic cancer in the remnant pancreas following initial pancreatectomy, and they
showed that the OS after repeated pancreatectomy for remnant pancreatic cancer was 14–35.5 months,
which was markedly longer than that noted for patients with unresectable pancreatic cancer in recent
studies [24]. Groot et al. performed a systemic review of the treatment of isolated local recurrence of
pancreatic cancer. Based on eight published studies including 100 patients who underwent re-resection
of recurrent pancreatic cancer, they concluded that local re-resection of recurrent pancreatic cancer may
be feasible, safe, and effective in the selected patients [33]. They demonstrated that the postoperative
morbidity and mortality rates were 29% and 1%, respectively. In addition, the median survival was
markedly higher (32 months) compared to that for other treatment modalities, such as chemotherapy
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(19 months) and radiotherapy (16 months). Zhou et al. reported that repeated pancreatectomy can be
safely performed in recurrent PDAC and showed good long-term results by conducting a literature
review from 2000 to 2016 with pooled analysis, which is the same analysis method as the present
study [32]. The present study was conducted for a literature review by adding case reports or case
series for the extended period.
The reason why patients with isolated local recurrence of pancreatic cancer have better prognosis
than those with other sites of distant dissemination of the disease is a matter of debate. What is the
reasonable basis for better survival in isolated local recurrence of pancreatic cancer? At first, taking
into account the biological background of isolated local recurrence patients, obtaining a survival
benefit through surgical treatment could be a well-founded treatment strategy. Research has shown
that pancreatic cancer is likely to be exposed to distant metastasis prior to surgical resection [42].
In an autopsy series, Haeno et al. revealed that a small subset of patients died with only locally
advanced disease, suggesting that some tumors may lack metastasis-promoting factors (or have
metastasis-suppressing factors) or may have metastases that are especially sensitive to systemic
chemotherapy [43]. This is thought to be directly related to the high median OS highlighted in the
present study. Furthermore, the role of adjuvant therapy is also significant. In the ESPAC-4 trial,
the patient group using the combination of gemcitabine with capecitabine showed a better DFS and
OS than the group of patients using gemcitabine alone [44]. This result should be considered for
one factor that improves survival. Although further study is necessary, the first surgery dissects the
soft tissue (nerve, lymphatics) and blocks the route to propagate the tumor to the surrounding area.
Besides, most patients recur in a highly attenuated state of potential residual cancer cells by adjuvant
chemotherapy after the first surgery. Therefore, there is a possibility that it remains purely isolated
recurrence, and there is room for improvement in oncologic outcome through repeated pancreatectomy.
Operating on a recurrent PDAC in the remnant pancreas is challenging as the procedure may
be associated with high morbidity or mortality due to adhesion of the tumor with the surrounding
tissue and anatomical deformation after the surgery. However, according to recent reports, repeated
pancreatectomy is safe [4]. According to our limited experiences, completion total pancreatectomy
for isolated recurrence in the remnant pancreas after initial pancreaticoduodenectomy is technically
demanding as a safe surgical procedure, especially when the previous pancreatic division line is above
the Superior mesenteric vein-splenic vein-portal vein confluence. Pancreaticojejunostomy associated
postoperative pancreatic fistula (POPF) may result in severe adhesion around these venous vascular
systems and the celiac axis where the remnant distal pancreas and these major vascular structures
should be dissected safely; thus, difficulties are encountered in performing repeated pancreatectomy.
Therefore, as Fortner suggested, the pancreatic division may be performed distal to the splenic artery
origin during the initial pancreaticoduodenectomy for resectable pancreatic cancer, considering the
possibility of subsequent repeated pancreatectomy for isolated recurrent pancreatic cancer in the
remnant pancreas [45].
Although long-term follow-up is required to address the potential role of repeated pancreatectomy
for recurrent pancreatic cancer, recent studies and the present pooled analysis strongly suggest the
oncologic benefits of this approach [36,37]. In the present study, the median OS was estimated to be
60 months from the time of repeated pancreatectomy and 107 months from the time of initial radical
pancreatectomy. Although the R1 resection rate after repeated pancreatectomy was higher than that
noted after the first pancreatectomy (8.5% vs. 15.5%, Table 2), the R1 resection rate was not associated
with the OS after pancreatectomy in univariate analysis (Table 3). Therefore, repeated pancreatectomy
is a challenging procedure, but preparing for R1 resection and attempting surgical treatment may
benefit the patient with respect to the OS.
In addition, it is quite difficult to differentiate between local recurrence and de novo carcinogenesis,
especially when the duration from the initial pancreatectomy is quite long. However, regardless of the
duration, the present pooled analysis showed that there was no difference with respect to survival after
repeated pancreatectomy was successfully performed. Therefore, medical oncologists and pancreatic
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surgeons should consider that the patients with isolated local recurrence in the remnant pancreas
following initial radical pancreatectomy may not show poor prognosis but may be able to survive
long-term if repeated pancreatectomy can be safely performed.
When reviewing the literature, it was found that isolated local recurrence is rare compared to
systemic recurrence following radical pancreatectomy for pancreatic cancer. Therefore, it is thought
that very selected cases were collected and analyzed, resulting in difficulty for generalization. However,
despite a rare recurrent pattern of resected pancreatic cancer, these patients are potentially encountered
in clinical practice. In addition, with the advance of laparoscopic technique, even laparoscopic repeated
pancreatectomy seems to be feasible in recurred pancreatic cancer [46]. What shall we do for them?
The present analysis may not be generalized but can at least provide potential treatment options for
the patients. Further experiences and investigations are mandatory to reveal the potential oncologic
role of local resection in isolated local recurrence of resected pancreatic cancer.
A limitation of the present study is that potential clinically important factors, such as tumor
differentiation, lymph node metastasis, and perineural invasion, were not considered in this
analysis. A more reliable analysis would have been possible if the original data of the cohort
study, including a relatively larger number of cases specifying clinic-pathological variables, could be
obtained. In the near future, a risk model for predicting isolated local recurrence following initial
pancreatectomy for pancreatic cancer should be developed based on data from a well-designed
multicenter collaborative study.
In conclusion, we revealed that repeated pancreatectomy for isolated local recurrence in the
remnant pancreas could improve survival outcomes based on the pooled analysis of data from published
studies. Hence, a case-specific surgical approach for repeated pancreatectomy for recurrent pancreatic
cancer, such as indications, the extent of surgery, and prognostic factors, should be established based
on consensus and more reliable, convincing data.
5. Conclusions
Repeated pancreatectomy cannot completely replace the role of adjuvant chemotherapy but
should be considered for patients with isolated local recurrent PDAC in the remnant pancreas.
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